
zzso pain in patients with cancer can be difficult to treat zzso 

The purpose of the study was to determine safety and efficacy of zzso a novel, zzso zzso zzso agent, in patients with advanced cancer and zzso pain of any zzso 

The study was a Phase zzso zzso zzso zzso dose escalation clinical zzso Patients with zzso zzso pain and advanced cancer were randomly assigned zzso to receive a maximum of eight single escalating doses of zzso or zzso ranging from zzso to zzso zzso The primary objective was safety and zzso The secondary objective was zzso measured by change in average pain intensity on a zzso zzso rating scale administered one week after the patient's final zzso 

zzso patients received treatment zzso zzso zzso zzso The most frequently reported adverse events were gastrointestinal symptoms, which were more frequent and severe with zzso than zzso two zzso zzso patients discontinued the study because of zzso and zzso At study zzso zzso exhibited a significant median decrease in pain intensity from baseline of zzso compared with zzso for zzso zzso The median for largest weekly reduction in target pain intensity was zzso for zzso and zzso for zzso patients zzso 

This zzso study for zzso in patients with advanced cancer and any type of zzso pain found gastrointestinal adverse events to be the zzso safety zzso The results also provided the first indication of clinical and statistical efficacy in reducing pain zzso 

